Resource Summary Report

Generated by RRID on Sep 2, 2026

OCI-Ly1

RRID:CVCL_1879
Type: Cell Line

Proper Citation

RRID:CVCL_1879

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1879

Proper Citation: RRID:CVCL_1879

Description: Cell line OCI-Ly1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma

Defining Citation: PMID:3567358, PMID:8574164, PMID:10676951, PMID:11807979, PMID:12169673, PMID:19278952, PMID:19358282, PMID:20628145, PMID:23257783, PMID:23292937, PMID:23699601, PMID:25960936

Comments: From: Ontario Cancer Institute (OCI); Toronto; Canada.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OCI-Ly1

Synonyms: OCI-LY1, OCI-ly1, OCI-LY-1, OCI-Ly-1, Oci-Ly-1, OCI-Ly 1, OCI-Ly01, OCI Ly1, Ly1, LY1

Cross References: EFO:EFO_0005907, BioGRID_ORCS_Cell_line:1211, cancercelllines:CVCL_1879, ChEMBL-Cells:CHEMBL4295427, ChEMBL-Targets:CHEMBL4296480, Cosmic:1134602, Cosmic:1295512, Cosmic:1329091, Cosmic:1517641, Cosmic:1541900, Cosmic:1629932, Cosmic:1636682, Cosmic:1945183, Cosmic:2276318, DSMZ:ACC-722, DSMZCellDive:ACC-722, ENCODE:ENCBS397COL, ENCODE:ENCBS729LWO, ENCODE:ENCBS899DSB, ENCODE:ENCBS945KYE, GEO:GSM1957, GEO:GSM380130, GEO:GSM552450, GEO:GSM1035341, GEO:GSM1059803, GEO:GSM1374783, GEO:GSM3150250, Lonza:1352,

PRIDE:PXD012087, Progenetix:CVCL_1879, PubChem_Cell_line:CVCL_1879, Wikidata:Q54931759

ID: CVCL_1879

Record Creation Time: 20220427T221355+0000

Record Last Update: 20260829T235504+0000

Ratings and Alerts

No rating or validation information has been found for OCI-Ly1.

No alerts have been found for OCI-Ly1.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 30 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Jha RK, et al. (2026) Dynamic Supercoiling Sponsors Transcription Amplification by MYC. bioRxiv : the preprint server for biology.

Demel UM, et al. (2026) Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(17), e11449.

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Qiao Q, et al. (2025) Metabolism-related ALDH1B1 acts as potential predictor and therapeutic target for primary gastrointestinal diffuse large B-cell lymphoma. Apoptosis : an international journal on programmed cell death, 30(5-6), 1482.

Rossi A, et al. (2025) Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma. iScience, 28(5), 112333.

Isshiki Y, et al. (2025) EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer cell, 43(1), 49.

Dang D, et al. (2025) Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis. Cancer cell, 43(6), 1159.

Manara P, et al. (2025) Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy.

Cancer research.

Prinz LF, et al. (2024) An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T??cells targeting CD80/86-upregulated DLBCL. Cell reports. Medicine, 5(2), 101421.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. Leukemia, 38(10), 2210.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Zhuang X, et al. (2024) Functional genomics identifies N-acetyllactosamine extension of complex N-glycans as a mechanism to evade lysis by natural killer cells. Cell reports, 43(4), 114105.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. Blood cancer discovery, 5(6), 417.

McNutt SW, et al. (2024) Phosphorylation-Driven Epichaperome Assembly: A Critical Regulator of Cellular Adaptability and Proliferation. Research square.

Gro?? E, et al. (2023) SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters. Cancers, 15(11).

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. Nature communications, 14(1), 3742.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. Cancer discovery, 13(1), 216.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. Cancer discovery, 13(8), 1862.

Schleser SW, et al. (2023) Palladium and Platinum Complexes of the Antimetabolite Fludarabine with Vastly Enhanced Selectivity for Tumour over Non-Malignant Cells. Molecules (Basel, Switzerland), 28(13).